@jcancom Hopefully, there will be a combo trial (with an anti-PD-1) in patients with liver mets as they correlate with reduced immunotherapy efficacy ...
@j Checkpoint blockade works in tumours types with mismatch DNA repair defects/p> However, most patients don't have such defects. So, one group ...
Trials (PhI/II) are now recruiting in both South Korea and the US (for patients with HCC), testing oral, IT, or a combo of both/p>
Preclinical data at AACR (the conference is next month) Activity of 3 Bromopyruvate in human tumor primary culture 3-dimensional explants using ...
Faeth Therapeutics is trying to exploit the differences in metabolism and nutrient uptake between healthy and cancerous cells by using a machine learn...
Dr. Yamamoto successfully sold his patents and related IP to Efranat, in late '09, who listing him as a ''co-founder'' (and inventor of GcMAF)/span> ...
@abidingtoday What Joe Tippens seems to have left out was that he took part in a clinical trial (testing Keytruda* +/- other approved drugs), while al...
@abidingtoday This could work/p> Also, some trials are discussed here (starting on page five)/p>
Vitamin C and Cancer: Is There A Use For Oral Vitamin C?/p> I haven't read that in full, but do know from this, ''However, it has been assumed t...
Preclinical data on a fasting mimicking diet/p>
@abidingtoday There are a number of ways THC/CBD can cause immunosuppressionhttps://www.sciencedirect.com/science/article/abs/pii/S0171298509000709/p>...
@abidingtoday I would be cautious about using cannabis with immunotherapy/p>
@j Lilly said it would price sintilimab similar to deeper discounted biosimilars, so about 40% off the wholesale acquisition cost, with the deci...
@jcancom I know another company is running a PhI/II testing a metabolic inhibitor (GAPDH, a-KGDH and NF-kB) in metastatic pancreatic, with stan...
@j Yes, and given for up to two years. I know Eli Lilly (and its partner, Innovent), wanted to disrupt the US anti-PD-1 market with sintilimab (star...
One company is working on first-in-class small molecules and this year should file an IND for its lead program which is a dual MCT1 and MCT4 inhibitor...
Turnstone Bio has struck a research collaboration with the Moffitt Cancer Center. It will support the progress of TIDAL-01 and other TIL candidates. M...
Yes, Cage Pharma wants to move forward with the microencapsulated formulation (given systemically). Hopefully, they will be able to do this, but I rem...
So a dose escalation to find the recommended phase 2 dose, followed by dose expansion cohort(s) of patients. Depending on the data and interactions wi...
@jcancom One company is seeking investment to move it into the clinic/p>
SSRI (selective serotonin reuptake inhibitors) antidepressants slowed the growth of pancreatic and colon cancers in mice, and when combined with a cer...
Replimune have provided an update. For the CERPASS trial (RP1 plus libtayo in advanced cutaneous squamous cell carcinoma), at current data cutoff (n=1...
Another company (Turnstone Bio) plans to test a neoantigen-reactive TIL therapy, then take forward an enhanced version (ex vivo expansion), and will c...
The company using the double positive (CD39+CD103+) TIL population should open a PhI trial in Q3. They are also working with another to 'silence' PD-1...
For PACT Pharma, the combo trial with an anti-PD-1 (up to six doses of Opdivo) should start to enrol patients early next year. NeoTCR-P201 and P211 ar...
The median starting dose from the two trials by Achilles was 15M cells, but with some changes to the ex vivo expansion, the highest dose level tested ...
The PhII is ongoing, with data for both endpoints expected this year. Also, a new paper. From it: ''Intranasal NEO100 was well tolerated at all ...
The IDSMC (Independent Data and Safety Monitoring Committee) has completed its first review of the ongoing, PhI/II CHIRON (advanced NSCLC) and THETIS ...
@daniel Thanks. Hopefully, there will be some more case reports, or a series published in the (near) future. As for development, I hope they have th...
In this paper, it was shown that inhibition of autophagy enhanced sensitivity to dual immune checkpoint inhibition (anti-CTLA-4 plus anti-PD-1)/p> ...